Sheldon Mullins
About Sheldon Mullins
Sheldon Mullins serves as the Senior Director of Regulatory Affairs at Ardelyx, Inc. since 2019 and has extensive experience in regulatory affairs across several biotechnology companies, along with a background in academia as an instructor at San Jose State University and UCSC Extension.
Work at Ardelyx
Sheldon Mullins has served as the Senior Director of Regulatory Affairs at Ardelyx, Inc. since 2019. In this role, he is responsible for overseeing regulatory strategies and ensuring compliance with industry standards. His tenure at Ardelyx spans five years, during which he has contributed to the company's regulatory initiatives.
Previous Experience in Regulatory Affairs
Before joining Ardelyx, Sheldon Mullins held the position of Senior Director of Regulatory Affairs at Adverum Biotechnologies, Inc. for six months in 2018-2019. He also worked at Achaogen as Senior Director of Regulatory Affairs from 2009 to 2010 and at Onyx Pharmaceuticals in a similar capacity from 2011 to 2014. His extensive experience includes roles at PDL BioPharma and Aquinox Pharmaceuticals, where he also served as Senior Director of Regulatory Affairs.
Education and Expertise
Sheldon Mullins holds a Master of Science in Business Analysis (MSBA) from San Francisco State University, Lam Family College of Business. He also earned a Bachelor of Arts in Chemistry from Sonoma State University. His educational background supports his expertise in regulatory affairs and business analysis within the pharmaceutical industry.
Teaching Roles
In addition to his regulatory affairs career, Sheldon Mullins has been an instructor at San Jose State University since 2011, contributing to the education of students for over 13 years. He also teaches at UCSC Extension in Silicon Valley, where he has been involved for 15 years, sharing his knowledge and experience in regulatory affairs and related fields.
Long-Term Industry Involvement
Sheldon Mullins has a significant history in the pharmaceutical industry, having worked at Genentech in various capacities from 1992 to 1999. His career spans multiple organizations and roles, reflecting a deep commitment to regulatory affairs and compliance in the biopharmaceutical sector.